Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences: Basic Science

In vivo evaluation of [18F]FECUMI101 as 5-HT1AR agonist PET ligand

Vattoly Majo, Jaya Prabhakaran, Matthew Milak, Norman Simpson, Lydumilla Savenkova, Mali Pratap, J. John Mann, Ramin Parsey and Dileep Kumar
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1177;
Vattoly Majo
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaya Prabhakaran
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Milak
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norman Simpson
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lydumilla Savenkova
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mali Pratap
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. John Mann
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramin Parsey
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dileep Kumar
1Psychiatry, Columbia University/NYSPI, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1177

Objectives The 5-HT1AR plays a critical role in several major neuropsychiatric and neurodegenerative disorders. We have recently synthesized several [11C]labeled agonist ligands, of which [11C]CUMI101 has been successfully developed as a PET ligand for imaging 5-HT1AR in human brain. In our efforts to develop a F-18 ligand to facilitate clinical application, we report the radiosynthesis and in vivo evaluation of [18F]FECUMI for the quantification of 5-HT1ARs in the high affinity state.

Methods Radiolabeling of [18F]FECUMI101 was performed in 2 steps by treating purified [18F]FEOTs with 1-2 mg desmethyl-CUMI-101 in DMSO in the presence of potassium carbonate followed by RP-HPLC. PET studies using an ECAT EXACT HR+ camera in 3D mode were performed in anesthetized baboon after an i.v. bolus injection of [18F]FECUMI and dynamic imaging over 3 hrs. Metabolite analyses were performed using a RP-HPLC method.

Results FECUMI101 is a selective 5-HT1AR agonist (Ki = 0.1 nM) ligand with an Emax of 80% in GTP-gammaS binding assays in CHO cell membranes stably expressing human 5-HT1AR. Radiosynthesis of [18F]FECUMI101 was achieved in 20-30% yield (EOS, 2 steps) with a specific activity of 1-2 Ci/micromol. PET studies in isofluorine anesthetized baboon showed good uptake and that [18F]FECUMI101 was retained in 5-HT1AR rich brain areas. The free fraction of [18F]FECUMI in baboon plasma was 37 ± 4% and radioactive metabolites were found to be polar. The specificity of the ligand uptake was determined by chase studies with the specific 5-HT1A antagonist WAY100635.

Conclusions PET studies in baboon indicate that [18F]FECUMI101 selectively binds to 5-HT1AR rich brain regions. Moreover, favorable brain and plasma metabolism kinetics, measurable plasma free fraction, high selectivity and specificity suggest that [18F]FECUMI101 is a suitable candidate as an [18F]labeled agonist PET imaging agent for the in vivo quantification of high-affinity 5-HT1AR in human subjects.

Research Support R21 MH08522

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In vivo evaluation of [18F]FECUMI101 as 5-HT1AR agonist PET ligand
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
In vivo evaluation of [18F]FECUMI101 as 5-HT1AR agonist PET ligand
Vattoly Majo, Jaya Prabhakaran, Matthew Milak, Norman Simpson, Lydumilla Savenkova, Mali Pratap, J. John Mann, Ramin Parsey, Dileep Kumar
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1177;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In vivo evaluation of [18F]FECUMI101 as 5-HT1AR agonist PET ligand
Vattoly Majo, Jaya Prabhakaran, Matthew Milak, Norman Simpson, Lydumilla Savenkova, Mali Pratap, J. John Mann, Ramin Parsey, Dileep Kumar
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1177;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences: Basic Science

  • Imaging of cerebral oxygen metabolism in the rat brain: An integrated PET/MRI study with O15-labelled gas
  • Assessment of glucose metabolism in a rat model of aging
  • 18FDG Rat brain atlas and comparison of brain FDG uptake after burn injury
Show more Neurosciences: Basic Science

Basic Science Posters (Neurosciences)

  • Assessment of glucose metabolism in a rat model of aging
  • Search of raphe nuclei in brainstem area by 18F-FDG imaging using PET-MRI fusion system
  • Synthesis and in vivo evaluation of a C-11 labeled novel dopamine D1 receptor agonist radioligand in baboon
Show more Basic Science Posters (Neurosciences)

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire